All webcasts and/or presentation slides from ESMO 2014 are now online!
ESMO’s flagship scientific journal, Annals of Oncology, publishes editorials, reviews, original articles and letters related to oncology
There are many good reasons to become an ESMO member. Find out why you should join Europe's leading medical oncology society.
OncologyPRO, a 360° research solution designed around YOU, is your single gateway to essential research & knowledge
L. Crino discusses current treatments available for stage IV squamous cell carcinoma of the lung and elaborates topline results from the REVEL study with docetaxel/ramucirumab in 2nd-line treatment for tumours of non-squamous and squamous histology, as well as the results from phase III study of gemcitabine/ cisplatin plus necitumumab in the 1st-line treatment of squamous cell carcinoma.
24 Oct 2014
Online abstract submission for the IMPAKT 2015 breast cancer conference is now open!
24 Oct 2014
Share your research! We are now accepting abstract submissions for #ELCC15
23 Oct 2014
There's still time to benefit from the early registration discount for ICHNO 2015 – the deadline had been extended to Wednesday 29 October. Register now!
22 Oct 2014
The changes concern lenalidomide, nilotinib and docetaxel
21 Oct 2014
Most of the ESMO Cancer Guides for Patients are now available in Greek. Download your copy now!
20 Oct 2014
EMA encourages patients to report suspected side effects
13 Nov - 16 Nov 2014
21 Nov - 22 Nov 2014
12 Feb - 14 Feb 2015
06 Mar - 06 Mar 2015
13 Mar - 14 Mar 2015
27 Mar - 28 Mar 2015